Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference

Rhea-AI Summary

Harrow (Nasdaq: HROW) will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 AM ET in Miami, Florida. The management presentation will be webcast live on the company website, with a replay available for approximately 90 days after the event.

News Market Reaction – HROW

+1.59%

17 alerts

+1.59% News Effect

-10.3% Trough in 29 hr 49 min

+$22M Valuation Impact

$1.43B Market Cap

1.3x Rel. Volume

On the day this news was published, HROW gained 1.59%, reflecting a mild positive market reaction. Argus tracked a trough of -10.3% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $1.43B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: March 10, 2026 Presentation time: 8:40 AM ET Webcast replay duration: 90 days +5 more

8 metrics

Conference date March 10, 2026 Leerink Partner’s 2026 Global Healthcare Conference presentation date

Presentation time 8:40 AM ET Scheduled time for Harrow’s conference presentation

Webcast replay duration 90 days Replay availability period on company website

Current share price $38.605 Price prior to conference news release

Price change 24h -27.96% One-day move ahead of the conference announcement

Volume today 3,933,324 shares Trading volume vs 20-day average of 694,680

52-week high $54.85 Reference level for current price positioning

52-week low $20.85 Reference level for current price positioning

Market Reality Check

Price: $36.17 Vol: Volume 3,933,324 is 5.66x...

high vol

$36.17 Last Close

Volume Volume 3,933,324 is 5.66x the 20-day average of 694,680, indicating unusually heavy trading ahead of this routine conference update. high

Technical Price $38.61 is trading below the 200-day MA of $39.92 and 29.62% under the 52-week high, but still 85.16% above the 52-week low.

Peers on Argus

HROW’s -27.96% move contrasts with peers showing modest, mixed performance (e.g....

1 Up 1 Down

HROW’s -27.96% move contrasts with peers showing modest, mixed performance (e.g., AMPH -2.56%, BGM -6.72%, BCRX +2.12%). Momentum scanner names (PCRX down, EVO up) also show no unified sector direction, pointing to stock-specific dynamics rather than a sector-wide shift.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Phase 3 trial plan	Positive	-28.0%	FDA cleared IND for Phase 3 TRIESENCE trial in cataract surgery setting.
Mar 02	Earnings and guidance	Positive	-28.0%	Reported record Q4 and 2025 revenue with 2026 revenue and EBITDA guidance.
Feb 18	Earnings date notice	Neutral	-1.3%	Announced timing of Q4 and year-end 2025 results and conference call.
Feb 17	Product launch news	Positive	+6.0%	Launched PharmaPack cash-pay kits as FDA-approved ophthalmic alternatives.
Feb 03	Competitive positioning	Positive	+5.1%	OSRX confirmed ongoing licensing and availability of compounded ophthalmic meds.

Pattern Detected

Recent news-linked moves show large negative reactions to major clinical and earnings updates, while product and competitive positioning news saw moderate gains.

Recent Company History

Over recent months, Harrow reported several milestones. On Mar 2, 2026, it announced record Q4 and full-year 2025 results with 2026 guidance, followed by a -27.96% reaction. On Mar 3, 2026, it received FDA clearance for a Phase 3 TRIESENCE® trial, again paired with a -27.96% move. Earlier, product initiatives like PharmaPack (Feb 17, 2026) and OSRX licensing news (Feb 3, 2026) coincided with gains near 5–6%. Today’s conference appearance fits into an active investor-relations cadence following these fundamental updates.

Market Pulse Summary

This announcement highlights Harrow’s participation at a major healthcare conference, with a March 1...

Analysis

This announcement highlights Harrow’s participation at a major healthcare conference, with a March 10, 2026 presentation that will be webcast and archived for 90 days. It follows recent earnings, guidance, and Phase 3 trial plans, suggesting continued engagement with the investment community. Investors may focus on any incremental commentary around these prior updates and watch trading volume, price relative to the 200-day moving average, and upcoming clinical or financial milestones.

Key Terms

ophthalmic, webcast

2 terms

ophthalmic medical

"a leading provider of ophthalmic disease management solutions in North America"

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

webcast technical

"The presentation will be webcast live and can be found on the Company’s website."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida.

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega, Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890

FAQ

When will Harrow (HROW) present at Leerink Partner’s 2026 Global Healthcare Conference?

Harrow will present on Tuesday, March 10, 2026 at 8:40 AM ET. According to the company, management will present in Miami and the session will be webcast live on the company website.

How can investors watch Harrow's (HROW) presentation on March 10, 2026?

Investors can watch via the company's live webcast on its website at the scheduled time. According to the company, a replay will be posted on the website and remain available for about 90 days.

Will there be a replay of Harrow's (HROW) Leerink presentation and for how long?

Yes, a replay will be available on the company website for approximately 90 days following the event. According to the company, the replay window begins after the live presentation on March 10, 2026.

Where is Leerink Partner’s 2026 Global Healthcare Conference presentation by Harrow (HROW) taking place?

The presentation will take place in Miami, Florida on March 10, 2026. According to the company, management will present in person while simultaneously offering a live webcast for remote viewers.

What time should shareholders tune in for Harrow's (HROW) presentation at the conference?

Shareholders should tune in at 8:40 AM ET on March 10, 2026 to watch the live presentation. According to the company, the presentation will be accessible via the company's investor website webcast.